Related Experiment Video
Updated: Apr 28, 2026
Pentylenetetrazole-Induced Kindling Mouse Model
Published on: June 12, 2018
Antiepileptic efficacy of lamotrigine in phenobarbital-resistant and -responsive epileptic rats: a pilot study
Claudia Brandt1, Wolfgang Löscher1
1Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Germany; Center for Systems Neuroscience, Hannover, Germany.
Abstract:
About 25% of patients with epilepsy are refractory to treatment, so that new, more effective antiepileptic drugs (AEDs) are urgently needed. Animal models that simulate the clinical situation with individuals responding and not responding to treatment are important to determine mechanisms of AED resistance and develop novel more effective treatments. We have previously developed and characterized such a model in which spontaneous recurrent seizures (SRS) develop after a status epilepticus induced by sustained electrical stimulation of the basolateral amygdala. In this model, prolonged treatment of epileptic rats with phenobarbital (PB) results in two subgroups, PB responders and PB nonresponders. When PB nonresponders were treated in previous experiments with phenytoin (PHT), 83% of the PB-resistant rats were also resistant to PHT. In the present study we examined if rats with PB resistant seizures are also resistant to lamotrigine (LTG), using continuous EEG/video recording of spontaneous seizures over 10 consecutive weeks. For this purpose, a new group of epileptic rats was produced and selected by treatment with PB into responders and nonresponders. As in previous studies, PB nonresponders had a significantly higher seizure frequency before onset of treatment. During subsequent treatment with LTG, all PB nonresponders and 60% of the PB responders exhibited >75% reduction of seizure frequency and were therefore considered as LTG responders. Plasma levels of LTG did not differ significantly between responders and nonresponders. The data of this pilot study indicate that LTG is more effective than PHT to suppress seizures in PB nonresponders in this model, but that not all PB responders also respond to LTG. Overall, our data provide further evidence that AED studies in post-SE TLE models are useful in determining and comparing AED efficacy and investigating predictors and mechanisms of pharmacoresistance.
Insights
New research shows lamotrigine (LTG) is more effective than phenytoin (PHT) in treating drug-resistant epilepsy in a rat model. This study highlights the importance of animal models for developing novel antiepileptic drugs (AEDs).
Area of Science:
- Neuroscience
- Pharmacology
- Epilepsy Research
Background:
- Approximately 25% of epilepsy patients exhibit drug resistance, necessitating the development of novel antiepileptic drugs (AEDs).
- Animal models are crucial for understanding AED resistance mechanisms and evaluating new treatments.
- A previously developed rat model of epilepsy, characterized by spontaneous recurrent seizures (SRS) post-status epilepticus, differentiates treatment responders and non-responders.
Purpose of the Study:
- To investigate the efficacy of lamotrigine (LTG) in a rat model of epilepsy with phenobarbital (PB) resistance.
- To compare the effectiveness of LTG against PB-resistant seizures with previously observed phenytoin (PHT) resistance.
Main Methods:
- Epileptic rats were treated with phenobarbital (PB) to establish responder and non-responder subgroups.
- Continuous electroencephalogram (EEG)/video monitoring was used over 10 weeks to record spontaneous seizures.
- Lamotrigine (LTG) was administered to PB non-responders and responders to assess seizure frequency reduction.
Main Results:
- All PB non-responders and 60% of PB responders showed a >75% reduction in seizure frequency with LTG, indicating LTG responsiveness.
- Plasma LTG levels did not significantly differ between LTG responders and non-responders.
- LTG demonstrated greater efficacy in suppressing seizures in PB non-responders compared to PHT in prior studies.
Conclusions:
- Lamotrigine (LTG) shows promise as a more effective treatment for phenobarbital (PB)-resistant epilepsy in this animal model compared to phenytoin (PHT).
- The study underscores the utility of post-status epilepticus temporal lobe epilepsy (TLE) models for evaluating AED efficacy and resistance mechanisms.
- Further research is warranted to explore predictors and mechanisms underlying pharmacoresistance in epilepsy.
Related Concept Videos
01:08Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:14Antiepileptic Drugs: Glutamate Antagonists
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...